Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.17 USD
-0.12 (-9.30%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $1.16 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Lineage Cell (LCTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.83 | $7.00 | $2.00 | 274.42% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Lineage Cell comes to $4.83. The forecasts range from a low of $2.00 to a high of $7.00. The average price target represents an increase of 274.42% from the last closing price of $1.29.
Analyst Price Targets (6 )
Broker Rating
Lineage Cell currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/8/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Not Available | Hold |
2/5/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
11/9/2023 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
10/20/2023 | Maxim Group | Michael Okunewitch | Not Available | Strong Buy |
10/19/2023 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
10/2/2023 | Dawson James Securities | Jason H Kolbert | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $4.83 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.04 |